Compass Therapeutics Business Summary

Compass Therapeutics, Inc. (CMPX) is a clinical-stage biopharmaceutical company that generates revenue primarily through strategic licensing agreements and the future commercialization of its proprietary antibody-based oncology pipeline. The company’s business segments are centered on the discovery and development of next-generation bispecific antibodies designed to engage the immune system against solid tumors and hematological malignancies. Its lead clinical programs include tovecimig (a DLL4 x VEGF-A bispecific), CTX-8371 (a PD-1 x PD-L1 bispecific), and CTX-10726 (a PD-1 x VEGF-A bispecific). Within the competitive landscape, Compass operates alongside firms such as Indivior, Terns Pharmaceuticals, ACADIA Pharmaceuticals, and Erasca. Compass distinguishes itself by targeting niche indications with high unmet needs, such as biliary tract cancer (BTC), where its lead asset has demonstrated superior objective response rates compared to standard-of-care therapies. Founded by Thomas Schuetz, MD, PhD, the company is led by a veteran executive team with deep expertise in oncology drug development and commercialization. Dr. Schuetz serves as the Chief Executive Officer and Vice Chairman, bringing a background in clinical medicine and biotechnology leadership. The leadership team was significantly bolstered in early 2026 with the appointments of Cynthia Sirard, MD, as Chief Medical Officer—formerly of Leap Therapeutics—and Arjun Prasad as Chief Commercial Officer, who previously led oncology launches at Servier and Genentech. Other key executives include Chief Financial Officer Barry Shin and Chief Scientific Officer Bing Gong. The company is backed by a high-pedigree investor base, including OrbiMed Advisors, F-Prime Capital, Tang Capital Management, and institutional giants such as BlackRock and Blackstone, providing a robust capital runway to support its clinical milestones through 2028.